The tweet was deleted by the author.
But we saved everything 🙂.
Zevra Therapeutics has partnered with GeneDx to introduce a sponsored genetic testing program for eligible patients in the U.S. suspected of having Niemann-Pick disease type C (NPC).
The initiative is aimed at improving early diagnosis and access to advanced testing for individuals facing this rare and challenging disorder. According to Zevra Therapeutics, the collaboration will expand availability of testing resources to better support patients and caregivers affected by NPC across the U.S. healthcare system.
The new initiative underscores Zevra Therapeutics’ commitment to advancing rare disease care, complementing the company’s continued efforts to expand its presence in the biopharmaceutical sector, as highlighted during its recent Nasdaq bell ceremony marking key milestones in its growth trajectory.